-
Views
-
Cite
Cite
Alana H.T. Nguyen, Mathieu Tremblay, Katharina Haigh, Ismaël Hervé Koumakpayi, Marilène Paquet, Pier Paolo Pandolfi, Anne-Marie Mes-Masson, Fred Saad, Jody J. Haigh, Maxime Bouchard, Gata3 antagonizes cancer progression in Pten-deficient prostates, Human Molecular Genetics, Volume 22, Issue 12, 15 June 2013, Pages 2400–2410, https://doi.org/10.1093/hmg/ddt088
- Share Icon Share
Abstract
Loss of the tumor suppressor PTEN is a common occurrence in prostate cancer. This aberration leads to the ectopic activation of the PI3K-Akt pathway, which promotes tumor growth. Here, we show that the transcription factor Gata3 is progressively lost in Pten-deficient mouse prostate tumors as a result of both transcriptional down-regulation and increased proteasomal degradation. To determine the significance of this loss, we used conditional loss- and gain-of-function approaches to manipulate Gata3 expression levels in prostate tumors. Our results show that Gata3 inactivation in Pten-deficient prostates accelerates tumor invasion. Conversely, enforced expression of GATA3 in Pten-deficient tissues markedly delays tumor progression. In Pten-deficient prostatic ducts, enforced GATA3 prevented Akt activation, which correlated with the down-regulation of Pik3cg and Pik3c2a mRNAs, encoding respectively class I and II PI3K subunits. Remarkably, the majority of human prostate tumors similarly show loss of active GATA3 as they progress to the aggressive castrate-resistant stage. In addition, GATA3 expression levels in hormone-sensitive tumors holds predictive value for tumor recurrence. Together, these data establish Gata3 as an important regulator of prostate cancer progression.